CORTICOTROPIN-RELEASING HORMONE (CRH)-BINDING PROTEIN INTERFERENCE WITH CRH ANTIBODY-BINDING - IMPLICATIONS FOR DIRECT CRH IMMUNOASSAY

被引:34
|
作者
LINTON, EA
PERKINS, AV
HAGAN, P
POOLE, S
BRISTOW, AF
TILDERS, F
CORDER, R
WOLFE, CDA
机构
[1] NATL INST BIOL STAND & CONTROLS,DIV ENDOCRINOL,POTTERS BAR EN6 3QG,HERTS,ENGLAND
[2] FREE UNIV AMSTERDAM,FAC MED,DEPT PHARMACOL,1081 BT AMSTERDAM,NETHERLANDS
[3] ST BARNABAS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND
[4] ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1677/joe.0.1460045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Direct immunoassay of plasma corticotrophin-releasing hormone (CRH) is potentially subject to interference from high levels of CRH-binding protein (CRH-BP) that exist in the human circulation. In this study, we tested the effect of CRH-free, native CRH-BP (6.4 nmol/l) purified from human plasma, CRH-BP diluent alone, normal human plasma (containing 5.8 nmol endogenous CRH-BP/l) and normal sheep plasma (containing no CRH-BP) on the binding of I-125-labelled CRH tracer to five N-terminal and four C-terminal CRH antibodies. All anti-(1-20)CRH N-terminal antibody dilution curves displayed marked inhibition of binding in the presence of purified CRH-BP and human plasma in comparison with the curves with the control diluent or sheep plasma. Almost no inhibition of binding was obtained with any of the C-terminal antibodies (all directed against epitopes within the last six amino acids of CRH) and the four dilution curves were nearly superimposable. Liquid-phase CRH IRMAs were then developed with different combinations of two of each of the N- and C-terminal antibodies, using radiolabelled IgG prepared from purified C-terminal antisera as tracer and raw N-terminal antisera as the link antibodies to the separating system. The addition of dilutions of purified CRH-BP over the range 1.25-20 nmol/l to the IRMA standard curve in assay buffer resulted in a dose-dependent reduction in the signal; with 5 nmol CRH-BP/l, a level commonly found in human plasma, the reduction in binding was 67% and 81% in two different IRMAs at a CRH concentration of 631 pmol/l. With endogenous CRH-BP in human plasma, a dose-dependent inhibition of binding similarly resulted, with the plasma containing the most CRH-BP causing the greatest inhibition. Since plasma CRH-BP levels in humans vary widely, direct plasma IRMA using these type of antibodies will give inaccurate results and initial extraction of the CRH is necessary. Methanol extraction of synthetic synthetic or endogenous CRH is shown to be both highly efficient and unaffected by variable amounts of endogenous or exogenous CRH-BP; it is therefore suitable as the first step in plasma CRH measurement by IRMA.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 50 条
  • [41] Mid-pregnancy levels of corticotropin releasing hormone (CRH) and its binding protein (CRH-BP) and risk of delivering preterm.
    Whitehead, NS
    Johnson, C
    Callaghan, W
    Williams, L
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 161 (11) : S116 - S116
  • [42] Corticotropin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRH1 antagonists
    Gilligan, PJ
    Hartig, PR
    Robertson, DW
    Zaczek, R
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 32, 1997, 32 : 41 - 50
  • [43] EFFECTS OF CORTISOL TREATMENT ON BRAIN AND ADRENAL CORTICOTROPIN-RELEASING HORMONE (CRH) CONTENT AND OTHER PARAMETERS REGULATED BY CRH
    BAGDY, G
    CALOGERO, AE
    SZEMEREDI, K
    CHROUSOS, GP
    GOLD, PW
    REGULATORY PEPTIDES, 1990, 31 (02) : 83 - 92
  • [44] Regulation of pituitary corticotropin releasing hormone (CRH) receptor mRNA and CRH binding during adrenalectomy: Role of glucocorticoids and hypothalamic factors
    RabadanDiehl, C
    Makara, G
    Kiss, A
    Zelena, D
    Aguilera, G
    JOURNAL OF NEUROENDOCRINOLOGY, 1997, 9 (09) : 689 - 697
  • [45] Corticotropin releasing hormone (CRH) is a neuroprotective peptide
    Hanstein, R
    Bayatti, N
    Behl, C
    Clement, A
    PHARMACOPSYCHIATRY, 2005, 38 (05) : 246 - 246
  • [46] Increased corticotropin-releasing hormone (CRH) expression in cutaneous lupus lesions
    Schmitz, M. K.
    Botte, D. A.
    Sotto, M. N.
    Borba, E. F.
    Bonfa, E.
    de Mello, S. B. V.
    LUPUS, 2015, 24 (08) : 854 - 861
  • [47] The effect of corticotropin-releasing hormone (CRH) on the adrenal medulla in hypophysectomized rats
    Hoheisel, G
    Schauer, J
    Scherbaum, WA
    Bornstein, SR
    HISTOLOGY AND HISTOPATHOLOGY, 1998, 13 (01) : 81 - 87
  • [48] A Novel Role of Peripheral Corticotropin-Releasing Hormone (CRH) on Dermal Fibroblasts
    Rassouli, Olga
    Liapakis, George
    Lazaridis, Iakovos
    Sakellaris, George
    Gkountelias, Kostas
    Gravanis, Achille
    Margioris, Andrew N.
    Karalis, Katia P.
    Venihaki, Maria
    PLOS ONE, 2011, 6 (07):
  • [49] ACUTE EFFECTS OF INTRACEREBROVENTRICULAR CORTICOTROPIN-RELEASING HORMONE (CRH) ON MACRONUTRIENT SELECTION
    LIN, L
    YORK, D
    BRAY, G
    APPETITE, 1992, 19 (02) : 199 - 199
  • [50] Expression and function of corticotropin-releasing hormone (crh) in anthropoid primate placenta
    Power, M. L.
    Bowman, M. E.
    Smiths, R.
    Layne, D. G.
    Ziegler, T. E.
    Tardif, S. D.
    Schulkin, J.
    AMERICAN JOURNAL OF PRIMATOLOGY, 2006, 68 : 40 - 41